Azilsartan medoxomil for the treatment of hypertension
Thomson Reuters, Barcelona, Spain.Drugs of today (Barcelona, Spain: 1998) (Impact Factor: 1.2). 09/2011; 47(9):647-51. DOI: 10.1358/dot.2011.47.9.1688573
The use of angiotensin receptor blockers (ARBs) represents a favorable approach for the control of blood pressure in patients with hypertension. Azilsartan medoxomil, a prodrug that undergoes rapid hydrolysis to its active moiety azilsartan, is an angiotensin AT(1) receptor antagonist with promising antihypertensive activity and a good safety profile. The agent has been evaluated as monotherapy and in combination with amlodipine or chlorthalidone in phase III trials in patients with essential hypertension. In 2011, azilsartan medoxomil was approved in the U.S. for the treatment of hypertension.
- [Show abstract] [Hide abstract]
ABSTRACT: New drugs introduced to the market every year represent privileged structures for particular biological targets. These new chemical entities (NCEs) provide insight into molecular recognition and also serve as leads for designing future new drugs. This annual review covers the synthesis of twenty-four NCEs that were approved for the first time in 2013 and two 2012 drugs which were not covered during the previous edition of this review. Copyright © 2015. Published by Elsevier Ltd.Bioorganic & medicinal chemistry 04/2013; 23(9). DOI:10.1016/j.bmc.2013.02.061 · 2.79 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.